Related Experiment Videos
Open clinical study of Madopar HBS
1Neurological Clinic, University of Berne, Switzerland.
European Neurology
|January 1, 1987
Summary
This study found that switching idiopathic Parkinson's disease patients to Madopar HBS often led to significant symptom worsening. Most patients experienced deterioration, necessitating early study discontinuation in several cases.
Area of Science:
- Neurology
- Pharmacology
Background:
- Idiopathic Parkinson's disease is a progressive neurodegenerative disorder.
- Madopar HBS is a modified-release formulation of levodopa and benserazide.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Madopar HBS in patients with idiopathic Parkinson's disease.
- To assess the impact of switching from standard Madopar to Madopar HBS.
Main Methods:
- An open-label study involving eleven patients with idiopathic Parkinson's disease.
- Patients were switched from standard Madopar to Madopar HBS, maintaining initial L-dopa dosage and frequency.
- Clinical assessments included Webster ratings and evaluation of symptomatology fluctuations.
Main Results:
- Nine out of eleven patients experienced marked clinical deterioration shortly after switching to Madopar HBS.
- Webster ratings worsened in six patients, remained unchanged in four, and improved in only one.
- No patients showed improvement in symptomatology fluctuations; five patients required premature study discontinuation due to unsatisfactory condition.
Conclusions:
- The initial switch from standard Madopar to Madopar HBS resulted in significant deterioration for most Parkinson's disease patients.
- Increasing L-dopa dosage did not consistently resolve the unsatisfactory clinical state.
- Alternative strategies like gradual switching or combination therapy might warrant further investigation.